were 90% of smokers given psilocybin off cigarettes a year later, versus the nicotine patch?
“90% of people addicted to tobacco compared to the nicotine patch one year later not smoking cigarettes.”
a guest, a mycologist said on Huberman Lab, 2026-11-16, at 1:15:57. hear it in context →
first, the part that holds
the direction is right. in the one randomized trial that compared psilocybin with the nicotine patch, about four times as many people in the psilocybin arm stayed off cigarettes. it was 40.5% versus 10.0% on prolonged abstinence at six months.
what we found when we went and looked
we found two primary sources, and neither has a 90% figure. the randomized trial (82 adult smokers, open-label, both arms also got 13 weeks of cognitive behavioral therapy) reported 6-month verified prolonged abstinence of 17/42 (40.5%) with one psilocybin dose versus 4/40 (10.0%) with the patch. the looser 7-day measure was 52.4% versus 25.0%. the trial paper says its 12-month results "will be published separately", and as of our search we found no publication of them. the only published 12-month number comes from an earlier uncontrolled pilot with 15 people, all given psilocybin: 67% were verified abstinent at 12 months and 60% at about 30 months.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| about 90% of tobacco-dependent people given psilocybin were not smoking one year later | overstated | no primary source we read reports 90%. the highest published 12-month figure is 67% (10/15), from an uncontrolled, open-label pilot with no comparison arm. in the randomized trial the best psilocybin-arm number is 52.4% on 7-day point prevalence, and that is at 6 months, not 12. its stricter primary outcome was 40.5%. [1][2] |
| at one year, far fewer people on the nicotine patch were not smoking | unverifiable | the only trial with a head-to-head patch arm published 6-month outcomes only. it states that 12-month results will be published separately. our PubMed search of 2026 psilocybin and smoking papers found no 12-month report from this trial. a one-year comparison against the patch cannot be checked against any published record yet. [1][3] |
| psilocybin outperformed the nicotine patch | confirmed | at 6 months, prolonged abstinence was 40.5% versus 10.0% (OR 6.12, 95% CI 1.99-23.26, P = .003). 7-day point prevalence was 52.4% versus 25.0% (OR 3.30, 95% CI 1.32-8.70). this comes from an 82-person open-label pilot in psychiatrically healthy adults. non-completers were counted as smoking. [1] |
| the result reflects psilocybin alone | misattributed | both arms received 13 weeks of manualized cognitive behavioral therapy. the comparison is one psilocybin dose plus therapy versus a patch course plus therapy. participants and investigators knew who got what, so expectancy effects cannot be separated out. the 15-person pilot also paired psilocybin with a structured therapy program. [1][2] |
both directions
for the speaker: the randomized trial points the speaker's way, with large effects. at 6 months, verified prolonged abstinence was about four times higher with psilocybin (40.5% vs 10.0%), and the 7-day measure was about double (52.4% vs 25.0%). no serious adverse events were attributed to either treatment. the earlier uncontrolled pilot reported 67% biologically verified abstinence at 12 months and 60% at about 30 months. that is high next to typical cessation outcomes, and it is likely where a "one year later" figure comes from.
against: the 90% figure does not appear in any record we read. the 12-month figure that does exist is 67%, from 15 people with no patch comparison. the trial that compared psilocybin with the patch has published only 6-month data. at 6 months, about half the psilocybin arm on the loose measure, and about 4 in 10 on the strict one, were not smoking. the trial was unblinded and small (82 people), and it enrolled only psychiatrically healthy adults. the patch arm also got 13 weeks of therapy, so the comparison is psilocybin plus therapy against patch plus therapy. a 2026 observational study comparing psilocybin-assisted care with standard care found no significant link with abstinence after adjustment (OR 1.82, 95% CI 0.68-4.86).
what this cannot say
we could not reach the PubMed article pages directly, so we read the abstracts through the NCBI E-utilities record and read the randomized trial in full on the journal site. our check for a published 12-month report covered PubMed records for 2026 psilocybin and smoking papers. a conference presentation or a paper indexed after our search could hold 12-month numbers we did not see. the speaker named no source, so we cannot rule out that the 90% refers to something unpublished, a subgroup, or a completers-only count. the 6-month figures come from one small, unblinded pilot. they say nothing about people with psychiatric conditions, who were excluded.
sources, each one fetched and read
- Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. JAMA Netw Open. 2026;9(3):e260972. doi:10.1001/jamanetworkopen.2026.0972. PMID 41805956 What we read there: 82 smokers, open-label, both arms got 13 weeks of CBT. 6-month biochemically verified prolonged abstinence: 40.5% psilocybin vs 10.0% patch (OR 6.12, 95% CI 1.99-23.26). 7-day point prevalence: 52.4% vs 25.0%. Fetched 2026-11-17 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/41805956/
- Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017. PMID 27441452 What we read there: open-label pilot, N = 15, all given psilocybin. biologically verified abstinence was 67% at 12 months and 60% at long-term follow-up (mean about 30 months). Fetched 2026-11-17 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/27441452/
- PubMed record summaries, 2026 papers matching psilocybin AND (smoking OR tobacco) What we read there: of the 12 matching 2026 records, none is a 12-month report from the psilocybin-versus-patch trial. one is an observational study, 'Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care' (Braz J Psychiatry 2026, PMID 42715291). its abstract, which we read, found psilocybin-assisted care not significantly associated with abstinence after adjustment (OR 1.82, 95% CI 0.68-4.86). Fetched 2026-11-17 (HTTP 200). https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&id=42715291,42616497,42609034,42539773,42538940,42379141,42325848,42262154,42224931,42212774,41479153
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam